Gala review
A brand cash price near thirteen hundred dollars sits beside a compounded yearly plan at a fraction of it.
The verdict
Gala publishes $1,299 a month as a cash price for branded Ozempic and $179 a month for compounded tirzepatide on a yearly subscription. Both are stated flat across doses, across fifty states.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 50
- From
- From $179/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- All 50 states
Gala sells branded semaglutide and compounded tirzepatide by injection, on terms that differ sharply by line. The Ozempic figure is a cash price that insurance may reduce. The tirzepatide figure requires a year's subscription.
Who writes the prescription, and what do they see?
A prescription precedes dispensing. The pages describe the two products rather than the clinician. That insurance may apply to one line implies a billing relationship the pages do not otherwise explain.
The gap between the two figures is not a discount and should not be read as one. A brand cash price and a compounded yearly plan describe different products on different terms. Comparing them against each other, or against another seller's monthly rate, compares things that are not alike.
What happens when the dose goes up?
Both lines are marked flat, so neither figure moves with the dose. The compounded page states all doses are included. What changes the tirzepatide price is the term, not the dose.
What the price includes
$1,299 a month is a cash figure and the pages state insurance may reduce it, which means the number a reader pays is unknown until a claim is run. Compounded tirzepatide is $179 a month on a yearly subscription, or $2,148 across twelve months. A three-month plan is $199 a month. No month-to-month rate is published before checkout.
What it claims, and what it cites
Ozempic is an FDA-approved brand product made by Novo Nordisk. The tirzepatide is compounded: a pharmacy prepares it, and the FDA does not review it before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: Coverage across all fifty states
- Strength: Both lines stated flat across doses
- Strength: Insurance is named as a possible reducer
- Limitation: The Ozempic cash price is $1,299 a month
- Limitation: The tirzepatide rate needs a yearly subscription
- Limitation: No month-to-month rate is published
- Limitation: No compounding pharmacy is named
What the evidence says about this kind of treatment
The assessment above is about Gala. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader with insurance that may apply to Ozempic, or one ready to commit a year to compounded tirzepatide.
- Wrong for
- A reader who wants to pay month to month without a commitment.
The evidence behind what Gala prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Gala compares
| Seller | Who it suits | Go |
|---|---|---|
 Green Cap Health | Readers in Texas wanting the lowest published figures | See Green Cap Health → |
 Harbor | Readers who value a bundled plan and will ask what raises the floor | See Harbor → |
 Glam Health | Readers who will ask what the plan costs at their own dose | See Glam Health → |
More GLP-1 telehealth sellers reviews: VitaFusions IVVital EdgeVitalex HealthVitara RXVitaStirVoxy
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Why is semaglutide $1,299?
- It is the cash price of branded Ozempic, and Gala states insurance may reduce it. What a reader pays is not established until a claim is run.
- Can I buy one month of tirzepatide at $179?
- No. The $179 is calculated on a yearly subscription. A three-month plan is $199 a month, and the month-to-month rate appears only at checkout.
- Does either price change with the dose?
- No. Both lines are stated flat across doses.
- Is Gala legit?
- Gala is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is Gala expensive compared with other GLP-1 telehealth sellers?
- Gala publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Gala below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.